Current Influenza Antiviral Drug Strategy Limitations and
Future Development of both Preventative and Intervention
Antiviral Therapies

Fahim      Ahmad

doi:10.2174/0127724344248640231010042648

[1]
Palese P, Shaw ML. Orthomyxoviridae: The viruses and their replication. In: Fields Virology.  5 th . Philadelphia: Lippincott-Raven Press 2007; pp. 1647-90.

[2]
Centers for Disease Control Prevention. 2011. Available from: http://www.cdc.gov/flu/about/disease/index.htm

[3]
Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis  2003; 188(1): 57-61.
 [http://dx.doi.org/10.1086/375799] [PMID: 12825171]

[4]
Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science  2009; 325(5937): 197-201.
 [http://dx.doi.org/10.1126/science.1176225] [PMID: 19465683]

[5]
Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA  2006; 295(8): 891-4.
 [http://dx.doi.org/10.1001/jama.295.8.joc60020] [PMID: 16456087]

[6]
Fang Q, Wang D. Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir. Biosaf Heal  2020; 2(2): 64-70.
 [http://dx.doi.org/10.1016/j.bsheal.2020.04.004]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0127724344248640231010042648	Print ISSN 2772-4344
Publisher Name Bentham Science Publisher	Online ISSN 2772-4352

Recent Advances in Anti-Infective Drug Discovery

Current Influenza Antiviral Drug Strategy Limitations and Future Development of both Preventative and Intervention Antiviral Therapies

Related Journals

Related Books